research use only
Cat.No.S9803
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Antioxidant Inhibitors | EGCG ((-)-Epigallocatechin Gallate) Tangeretin (+)-Catechin Hydroxygenkwanin Silymarin (-)Epicatechin DMU-212 Oleuropein Syringic acid Cocoa Extract |
|
In vitro |
Water : 100 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 639.79 | Formula | C32H49N9O5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 736992-21-5 | -- | Storage of Stock Solutions |
|
|
| Synonyms | D-Arg-Dmt-Lys-Phe-NH2 | Smiles | CC1=C(CC(NC(=O)C(N)CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CC2=CC=CC=C2)C(N)=O)C(=CC(=C1)O)C | ||
| Targets/IC50/Ki |
cytochrome c peroxidase
|
|---|---|
| In vitro |
Elamipretide (SS-31, MTP-131) binds with high affinity to cardiolipin, an anionic phospholipid expressed on the inner mitochondrial membrane that is required for cristae formation. In addition, the complex of this compound with cardiolipin inhibits cytochrome c peroxidase activity, which catalyzes cardiolipin peroxidation and results in mitochondrial damage during ischemia, by protecting its heme iron. |
| In vivo |
Pretreatment of rats with Elamipretide (SS-31, MTP-131) protects cristae membranes during renal ischemia and prevents mitochondrial swelling. Prompt recovery of ATP on reperfusion leads to rapid repair of ATP-dependent processes, such as restoration of the actin cytoskeleton and cell polarity. Rapid recovery of ATP also inhibits apoptosis, protects tubular barrier function, and mitigates renal dysfunction. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05194631 | Recruiting | Diaphragm Injury|Mechanical Ventilation Complication |
University Hospital Montpellier |
February 18 2022 | Not Applicable |
| NCT02914665 | Completed | Heart Failure |
Stealth BioTherapeutics Inc. |
October 20 2016 | Phase 2 |
| NCT02848313 | Completed | Age-Related Macular Degeneration |
Stealth BioTherapeutics Inc. |
October 28 2016 | Phase 1 |
| NCT02814097 | Completed | Chronic Heart Failure |
Stealth BioTherapeutics Inc.|Charite University Berlin Germany|SCIRENT Clinical Research and Science d.o.o. |
September 2 2016 | Phase 2 |
| NCT02436447 | Completed | Normal and Impaired Renal Function |
Stealth BioTherapeutics Inc. |
May 2015 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.